Sackler Family’s OxyContin Firm To Face Suit From Native Americans

The prescription opioid painkiller OxyContin is displayed at a drugstore. Image by Getty Images
The OxyContin manufacturer Purdue Pharma, along with two dozen other opioid makers, are facing a lawsuit brought by three Native American tribes in the Dakotas, claiming that the firms hid the drug’s risk.
Purdue is privately owned by the Sackler family, who are Jewish. (After the publication of this brief, a representative for one branch of the family, the descendants of Arthur M. Sackler, contacted the Forward to note that their branch sold their share of the firm in the 1980s and has never benefited from the sale of OxyContin.)
According to the Associated Press, the three tribes are asking for monetary damages and a fund to pay for addiction treatment.
“This epidemic has overwhelmed our public-health and law-enforcement services, drained resources for addiction therapy, and sent the cost of caring for children of opioid-addicted parents skyrocketing,” Brendan Johnson, a lawyer representing the tribes, told the AP.
Native American populations in South Dakota have been disproportionately affected by the opioid crisis.
Contact Josh Nathan-Kazis at [email protected] or on Twitter, @joshnathankazis.
This is a moment of great uncertainty. Here’s what you can do about it.
We hope you appreciated this article. Before you go, we’d like to ask you to please support the Forward’s independent Jewish news this Passover. All donations are being matched by the Forward Board - up to $100,000.
This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.
With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give this Passover is invested in the future of the Forward — and telling the American Jewish story fully and fairly.
The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

